Last reviewed: April 25, 2026 — Reviewed by: ZYNDIO Editorial Team

Finasteride 101: How It Works, What to Expect, and Who It's For

Finasteride has been on the U.S. market for hair loss since 1997, when the FDA approved 1 mg daily oral finasteride (Propecia) for male pattern hair loss based on Phase III trials showing measurable hair count improvement vs placebo at 12 and 24 months. Twenty-eight years later, finasteride remains one of two FDA-approved oral medications for androgenetic alopecia, and the longest-followed by far. This article walks through the mechanism, the published clinical data, the realistic expectations, and the side effect questions that get the most attention online.

The molecule and what it does

Finasteride is a 5-alpha-reductase inhibitor. The 5-alpha-reductase enzyme converts testosterone to dihydrotestosterone (DHT). DHT is the dominant androgen at the hair follicle in male pattern baldness, where it progressively miniaturizes terminal hairs into vellus hairs over years to decades.

Finasteride at 1 mg daily inhibits Type II 5-alpha-reductase, reducing serum DHT by approximately 70% and scalp DHT by a similar margin (Drake et al., J Am Acad Dermatol). Reducing the DHT signal at the follicle slows or reverses the miniaturization process, allowing hairs to remain in the growing (anagen) phase longer.

Finasteride 5 mg daily (Proscar) is also FDA-approved for benign prostatic hyperplasia. Hair loss dosing is 1 mg.

What the long-term data shows

The longest published follow-up of finasteride for male pattern hair loss is the Kaufman et al. 5-year extension of the original Phase III trials, which reported that 90% of finasteride-treated men either improved or stabilized their hair count at 5 years, vs 25% of placebo-treated men (Kaufman et al., J Am Acad Dermatol). A 10-year Japanese observational study reported similar trends.

The clinically realistic interpretation: finasteride is more effective at preventing further loss than at regrowing hair that has already been lost. Patients who start earlier — before substantial miniaturization has occurred — see better long-term results.

What "results" look like in practice

The expected timeline:

  • Months 1-3. No visible change. A subset of patients experiences a brief shedding phase as miniaturized hairs are pushed out and replaced.
  • Months 3-6. Stabilization in most responders. Hair quality and density may begin to subtly improve.
  • Months 6-12. Visible improvement in most responders. This is the standard window for evaluating whether finasteride is working.
  • Year 2 and beyond. Sustained results require continued treatment. Discontinuation generally leads to reversion to the pre-treatment trajectory within 12 months.

Photographs at month 0, month 6, and month 12 — under consistent lighting and angle — are the most reliable way to evaluate response. Mirrors in different bathrooms can produce dramatically different impressions of the same scalp.

Who responds best

Best responders share several characteristics:

  • Younger age at start (20s and 30s).
  • Less advanced miniaturization (Norwood scale II-IV rather than V-VII).
  • Hair loss confined to crown and mid-scalp (where the bulk of the trial data was generated) — finasteride has shown more variable results at the frontal hairline.
  • Consistent daily adherence.

Patients with long-standing advanced miniaturization may stabilize on finasteride but should not expect dramatic regrowth.

Side effects: what is documented vs what is debated

The FDA-approved label lists sexual side effects (decreased libido, erectile dysfunction, ejaculation disorders) at low single-digit incidence in the original trials. A widely-discussed phenomenon — persistent post-finasteride syndrome (PFS) — is the subject of ongoing investigation.

The honest summary of the current evidence:

  • The original trials reported sexual side effects at low rates that resolved on discontinuation in the great majority of cases.
  • Post-marketing reports describe a smaller subset of patients with sexual or neuropsychiatric symptoms persisting after discontinuation.
  • Causation is contested. Multiple large observational studies have produced mixed findings (JAMA Dermatology 2017 nocebo analysis).
  • The FDA updated the U.S. label in 2012 to include language about persistent erectile dysfunction reports.

A clinician walking a patient through this decision will typically discuss the symptom-monitoring plan up front, recommend reporting any new symptoms early, and treat dose reduction or discontinuation as appropriate first responses if symptoms emerge.

Topical finasteride: a different option

Topical finasteride was FDA-cleared as part of a combination product with minoxidil in 2024 in some markets, and has been compounded for years prior. The systemic DHT suppression with topical finasteride is meaningfully lower than with oral 1 mg, which is the rationale some patients prefer it. Comparative efficacy vs oral finasteride at scalp DHT reduction has been studied in small trials with broadly comparable hair-count outcomes (Caserini et al., Skin Pharmacol Physiol). Off-label use should be discussed with your clinician.

Dutasteride: the more potent cousin

Dutasteride inhibits both Type I and Type II 5-alpha-reductase and produces deeper DHT suppression. It is FDA-approved for benign prostatic hyperplasia in the U.S. and is approved for hair loss in some countries (notably South Korea). U.S. use for hair loss is off-label. Some dermatologists use 0.5 mg dutasteride daily for finasteride non-responders or for patients seeking a stronger effect, with a side effect profile that is qualitatively similar to finasteride.

What finasteride does not do

  • Finasteride does not regrow hair on areas that have been bald for many years.
  • Finasteride does not slow body hair growth (DHT regulates body hair differently than scalp hair).
  • Finasteride does not affect the rate of male pattern baldness in patients without ongoing miniaturization (i.e., in stable hair).
  • Finasteride is not used for female pattern hair loss outside of postmenopausal patients in specific specialist contexts.

FAQ

Is finasteride a lifelong commitment? Continued treatment is required to maintain results. Discontinuation generally leads to reversion within 6-12 months.

Should I take finasteride and minoxidil together? Combination therapy targets two different pathways (DHT signaling and follicular blood flow / growth phase prolongation). Combination is generally more effective than monotherapy for moderate-to-advanced hair loss.

Can I take finasteride every other day? Pharmacokinetics suggest the half-life supports plausible activity at every-other-day dosing, but clinical trial evidence is for daily 1 mg. Dosing variations should be discussed with your clinician.

Will finasteride affect my workout or testosterone level? Total testosterone typically rises modestly (10-20%) on finasteride because conversion to DHT is reduced. Free testosterone changes are smaller. The effect on muscle and athletic performance has not been shown to be clinically significant in published trials.

Do I need lab monitoring? Routine lab monitoring is not standard for healthy men on finasteride for hair loss. PSA can be modestly suppressed, which is a consideration if the patient is also being screened for prostate concerns — inform the screening clinician.

Medical Disclaimer: This content is educational and is not medical advice. Individual results vary. Off-label use should be discussed with your clinician. Compounded medications are prepared by FDA-registered compounding pharmacies but are not FDA-approved as a finished drug product.